CRISPR Therapeutics AG entered into an amendment to the Amended and Restated Joint Development and Commercialization Agreement with Vertex Pharmaceuticals Incorporated and Vertex Pharmaceuticals (Europe) Limited, involving the global development, manufacturing, and commercialization of exagamglogene autotemcel.